Research site
Weston, Florida 33331
2 studies enrolling now · 14 studies all time
What they study most
AL Amyloidosis, Acute Ischaemic Stroke, Anemia, Cancer, Cerebral Stroke, Cerebrovascular Stroke, Epithelial Ovarian Cancer, Hypercalcemia, Hyperparathyroidism, Primary, Idiopathic Pulmonary Fibrosis (IPF), Intracerebral Hemorrhage, Ischemic Attack, Transient
Studies at this site
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer — Recruiting now
- A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. — Recruiting now
- A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM — Running, not enrolling
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) — Running, not enrolling
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) — Running, not enrolling
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CM — Running, not enrolling
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) — Completed
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy — Stopped early
- Abituzumab in SSc-ILD — Stopped early
- Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy — Completed
- [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] — Completed
- Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications — Completed
- Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke — Completed
- Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke — Completed